Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Donald Carson

Sports Medicine Baton Rouge, LA Doctor of Osteopathy

NPI 1245595040 CMS profile 370470

7566 Picardy Ave, Baton Rouge, LA 70808

Open in the dashboard

General payments

$8,411

487 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Donald Carson of Baton Rouge, LA is reported in the CMS Open Payments database as having received $8,411 across 487 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $133 3
2022 General $1,981 108
2021 General $2,326 147
2020 General $1,522 89
2019 General $2,448 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Carson
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Donald Carson were reported at $0. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Donald Carson Sports Medicine median Middle half National median
2019 $2,448 $119 $35–$362 $163
2020 $1,522 $77 $24–$275 $114
2021 $2,326 $104 $28–$340 $132
2022 $1,981 $94 $31–$272 $149
2023 $133 $91 $34–$271 $160
2024 $0 $126 $38–$294 $164
2025 $0 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $1,100 34 payments
  2. Novo Nordisk Inc $1,004 65 payments
  3. AbbVie, Inc. $671 60 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $579 26 payments
  5. Lilly USA, LLC $502 40 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $406 21 payments
  7. Allergan Inc. $383 31 payments
  8. Amgen Inc. $373 23 payments
  9. Sanofi-Aventis U.S. LLC $345 23 payments
  10. Amarin Pharma Inc. $332 14 payments
  11. Other $2,716 150 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $8,411 487 payments
Products named General payments · program years 2019–2023
  1. Ozempic $655 53 payments
  2. FARXIGA $655 25 payments
  3. RYBELSUS $596 43 payments
  4. TRINTELLIX $389 15 payments
  5. JARDIANCE $381 19 payments
  6. UBRELVY $346 31 payments
  7. Kerendia $321 8 payments
  8. Repatha $308 20 payments
  9. TRULICITY $305 25 payments
  10. Saxenda $278 10 payments
  11. Other $7,127 439 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

330

Median for Emergency Medicine: 88

Drug cost

$3,447

Median for Emergency Medicine: $590

Branded share of claims

24.8%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fentanyl Generic 12 $848
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 13 $678
Gabapentin Generic 18 $395
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 13 $182
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 26 $175
Fluticasone Propionate Generic 12 $165
Clindamycin Hcl Generic 18 $134
Azithromycin Generic 35 $126
Doxycycline Hyclate Generic 19 $120
Ciprofloxacin Hcl Generic 26 $114

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$11,455

Of which drugs: $55

Medicare patients

149

Average age 70

Services billed

412

88 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 38%
Ischemic heart disease 36%
COPD 26%
Depression 26%
Chronic kidney disease 24%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Facility 12 90 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

487 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record